Listen

Add to my selection

BAVENCIO

Medicine - Posted on Nov 09 2023

Active substance (DCI)

avelumab

history (5)

10/4/23

BAVENCIO (avelumab) - Merkel cell carcinoma (MCC)

-

CAV :
54321

icône flèche
3/3/21

BAVENCIO

Key points Favourable opinion for reimbursement as monotherapy for the first-line maintenance treatment of adult patients wi...

CAV :
54321

icône flèche
5/13/20

BAVENCIO

New indication Key points Favourable opinion for reimbursement of BAVENCIO (avelumab) in combination with axitinib in the fi...

CAV :
54321

icône flèche
3/18/20

BAVENCIO (avelumab)

Key points Favourable opinion for reimbursement as monotherapy for the treatment of adult patients with metastatic Merkel ce...

CAV :
54321

icône flèche
9/19/18

BAVENCIO (avelumab), anti-PDL1 antibody

High clinical benefit as monotherapy, in adults previously treated with chemotherapy, for the treatment of metastatic Merkel...

CAV :
54321

icône flèche

Technical information

ATC code

L01FF04

Manufacturer

MERCK SERONO

Presentation

BAVENCIO 20 mg/mL, solution à diluer pour perfusion (code CIS : 60199966)
1 flacon(s) en verre de 10 ml (CIP : 34009 550 415 2 8)

All our publications

Endocrine gland cancers

Nervous system cancers

Skin and connective tissue cancers

Urologic cancers